

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61B 18/12</b>	<b>A1</b>	(11) International Publication Number: <b>WO 97/41793</b>
		(43) International Publication Date: 13 November 1997 (13.11.97)

(21) International Application Number: PCT/NL97/00223

(22) International Filing Date: 25 April 1997 (25.04.97)

(30) Priority Data:  
1003024 3 May 1996 (03.05.96) NL(71)(72) Applicant and Inventor: JACOBS, Clemens, Josephus  
{NL/NL}; Veenlanden 40, NL-3871 RD Hoevelaken (NL).


(72) Inventor; and

(75) Inventor/Applicant (for US only): SIE, Tjong, Hauw {NL/NL};  
Prinses Julianastraat 49, NL-8019 AT Zwolle (NL).(74) Agent: BARENDREGT, F.; Van Exter Polak & Charlois B.V.,  
P.O. Box 3241, NL-2280 GE Rijswijk (NL).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT,  
UA, UG, US, UZ, VN, YU; ARIPO patent (GH, KE, LS,  
MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI  
patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,  
SN, TD, TG).

Published

With international search report.

(54) Title: INSTRUMENT FOR INTERRUPTING CONDUCTION PATHS WITHIN THE HEART



## (57) Abstract

A description is given of a probe for making stripe-shaped transmural lesions in one or more walls of the atria of the heart in open-heart surgery. The stripe-shaped lesion blocks electrical impulses in a direction crosswise to the lesion. The probe has a handle (1), a closed end (2) and a relatively rigid shaft (5), and means (6, 7) for coupling the probe to an RF power source.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INSTRUMENT FOR INTERRUPTING CONDUCTION PATHS WITHIN THE HEART

The invention relates to an instrument for making at least one stripe-shaped transmural lesion in one or more walls of the atria of the heart, which lesion essentially blocks the electrical impulse conduction in a direction crosswise to the stripe-shaped transmural lesion.

All kinds of heart arrhythmias, and in particular chronic and paroxysmal atrial fibrillation, can currently be treated by surgery.

A known surgical procedure (MAZE) was designed to eliminate atrial fibrillation permanently. In this procedure incisions are made with a scalpel in the walls of the atria, in order to block, by the thus formed interruption of the tissue continuity electrical impulse conduction in a direction crosswise to the incisions. As a result of the subsequent scarring, these electrical blocks acquire a permanent character.

This known technique is as yet performed only to a limited extent worldwide, owing to the complexity of the operation. The increased risk is particularly associated with the duration of the operation and the way in which the operation has to be carried out.

The duration of the operation, and in particular the cross-clamp time (x-clamp) is so long that there is a great risk of damage to the heart muscle.

The cross-clamp time required for the MAZE procedure alone is currently still an average of 68 min. (range 50 - 102 min.), and the necessary time on the heart-lung machine is on average 182 min. (range 130 - 256 min.). For further data you are referred to Atrial Fibrillations: Mechanisms and Therapeutic Strategies, Futura Publishing Co. Inc. Armonk, N.Y. 1994. J.L. Cox: Surgical Interruption of Atrial Reentry as a Cure for Atrial Fibrillation. The way in which the operation is performed with the scalpel produces an increased risk of vascular suture leaks and subsequent bleeding, due to the large number and location

of the vascular sutures involved.

The object of the present invention is to provide an instrument of the abovementioned type which eliminates the abovementioned disadvantages, and which in particular  
5 shortens the time required for the operation and reduces the risk of bleeding and damage, therefore reducing the risk for the patient in open-heart surgery.

According to the invention, the instrument indicated is characterized in that the instrument is a  
10 probe in which the end which during the operation comes into contact with the wall to be treated is a closed electrode which can interact with an RF power source, while the probe is of a relatively rigid type.

The instrument according to the invention is a  
15 probe by means of which in open-heart surgery it is possible to make a permanent change in an atrial wall which is transmural, i.e. it extends over the entire thickness of the wall.

As will be discussed at a later stage, during the  
20 performance of the operation the electrode at the end of the probe is brought into contact with the atrial wall to be treated and is moved along it in a linear pattern. On excitation of the electrode with RF power, dielectric (RF) heating of the wall tissue occurs. The RF treatment  
25 produces a change in the cell structure of the atrial wall, with the result that electrical impulse conduction in a direction crosswise to the transmural lesion is blocked.

In order to be able to work well with it, the probe must be of a relatively rigid type, so that the electrode  
30 can be accurately positioned on and moved along the atrial wall. In the operation no disintegration of the tissue of the atrial wall occurs, and there is no risk of subsequent bleeding. The operation can be carried out on the outside or the inside of the atrium as desired.

35 Methods of RF heating or dielectric heating are based on the use of heat generated in materials which are relatively poor electrical conductors when they are placed in high-frequency electromagnetic fields. The heat is generated as a result of dielectric losses occurring in a

material situated between metal electrodes which form a capacitor which is connected to a high-frequency (RF) generator. Such heating is highly uniform and therefore extremely suitable for use of the instrument, the probe, according to the invention. During use of the probe, one of the capacitor "plates" is formed by the electrode at the end of the probe, while the other "plate" is a counter-electrode which is stuck on, for example, the patient's back; when the latter electrode is being placed, it is preferable to use a contact gel which has electrical conductance. Of course, the counter-electrode can also be placed on the outside of the atrial wall of the heart, for example if the electrode of the probe is being brought into contact with the inside of said wall.

In connection with the invention, reference is made to WO 95/03742, which discloses a catheter comprising at the distal a metal electrode by means of which tissue erosion, also known as ablation, can be carried out.

Such a catheter typically has a length of approximately 1 metre, a diameter of approximately 2 mm, and has an electrode of approximately 2 mm diameter, and its low thickness makes it very flexible, so that it can follow a blood vessel without any problems. This catheter is suitable for local punctate ablation. Such a catheter is not suitable for use as a probe for making stripe-shaped transmural lesions in an atrial wall.

In particular, the probe according to the invention has at least a handle; an end; a relatively rigid shaft between the handle and the end, and connecting and conduction means for connecting the end of the probe to an RF power source.

In the instrument according to the invention a temperature recorder is advantageously present near the end of the probe, which temperature recorder, operating in a feedback system with the RF power source, can regulate the temperature of the end of the probe to a preset value. Through input of the RF power, the temperature of the end of the probe will generally rise; feedback with the RF power source makes it possible to ensure that the

temperature of the end does not exceed a predetermined value.

With use of RF power it is extremely important that the fewest possible electrical blockages should be present in the body section between the end of the probe and the counter-electrode on the outside of the body. On account of this, it is preferable to ensure that the probe can interact with means for supplying a physiologically acceptable liquid to the end thereof. In its simplest form, such a liquid is supplied near the electrode of the probe by way of a line which does not form part of the probe. The function of the liquid is, on the one hand, to cool the electrode and, on the other, to prevent the occurrence of electrically insulating air gaps which adversely affect the efficiency of the RF action.

It is very advantageous for the probe according to the invention itself to have means for discharging a physiologically acceptable liquid near the end of the probe. Said liquid will generally preferably have a certain degree of electrical conduction, and is expediently a physiological salt solution.

In a very attractive embodiment, the instrument has between the handle of the probe and the shaft inlet means for introducing the physiologically acceptable liquid, which inside the shaft remains electrically insulated from the connecting and conduction means present in the shaft, while near the end it has outflow means for the physiologically acceptable liquid. With this embodiment, the functioning of the probe can be improved yet further, and it can be ensured that the greatest RF energy effect is concentrated in the wall of the atrium to be treated, forming the desired transmural lesion.

At the side of the handle facing away from the end of the probe, the conduction and connecting means of the probe according to the invention comprise a connector connected thereto, with contact means for connection of the electrode to the end of the probe and the temperature recorder present therein to the RF power source.

The connector is preferably of the rapid coupling

type, so that easy coupling to the RF power source is permitted.

In order to make handling of the instrument according to the invention, in the form of a probe, as easy  
5 as possible for the operating surgeon during an open-heart operation, the shaft of the probe preferably has an intrinsic curvature, which is expediently approximately 140°.

The invention will now be explained with reference  
10 to the drawing, in which:

- Figure 1 shows a schematic picture of the transmural lesions which can be made with the instrument according to the invention, and which can block electrical impulses in directions crosswise to said lesions;

15 - Figure 2 shows an instrument according to the invention in a first embodiment;

- Figure 3 shows an instrument according to the invention in a second embodiment.

Figure 1 shows diagrammatically in a two-dimensional view the two atria of a human heart, in which the  
20 transmural lesions are indicated by reference letter C, the undisturbed electrical impulses by A, and the blocked electrical impulses by B. The lesions C are in the nature of scar tissue which is formed after treatment using the  
25 probe according to the invention.

Figure 2 shows a probe according to the invention in a first embodiment, and shows a handle 1, an active metal end 2 as a closed electrode with indication of the position of a temperature sensor 3. The shaft of the probe  
30 5 has a curvature 4 of approximately 140°, and inside the shaft run the electrical wires 6 for exciting the closed electrode-type end 2 and wire 7 for connecting the temperature sensor which is fitted at the position of reference number 3.

35 Inside the handle 1 are electrical switch means 10 (not shown in any further detail) for permitting connection of the probe to the RF generator (not shown). Reference numbers 8 and 9 also indicate a connector making it possible to couple the probe to the RF generator.

Figure 3 shows a particularly advantageous embodiment of the probe according to the invention, which is identical to the probe of Figure 2, but in which reference number 11 indicates a Y-connector which makes it possible to supply a physiologically acceptable liquid by way of a port 12 into the shaft 5, said physiologically acceptable liquid being guided through the shaft 5 without contact with the conduction means 6 and 7. The physiologically acceptable solution flows by way of the port 12 to an inner shaft 13, and from there by way of the shaft 5 to the outflow ports 14 which are disposed in the vicinity of the metal end 2. The physiologically acceptable liquid is expediently a physiological salt solution which is readily tolerated by the body.

The physiological salt solution, on the one hand, achieves cooling of the closed electrode 2 and, on the other hand, lowers the electrical resistance between the closed electrode of the end 2 and the atrial wall. Extremely good and reproducible results are obtained with the probe shown in the figure. The source of RF power is typically a generator which can deliver a power of, for example, maximum 50 watt at a frequency of 500 kHz. The power supplied is a function of the temperature set and the tissue contact of the electrode forming the end of the probe. The desired temperature can be set at the generator, and in general lies in the range 50 to 70°C. If temperatures higher than the given range are permitted, burning of the tissue (coagulation) will occur, with the result that an insulating layer is formed; said layer will make further action of the RF energy difficult, with the result that underlying tissue is not treated fully, if at all.

The end 2 of the probe expediently comprises platinum and is typically a cylindrical shape with a diameter of 4 mm. The diameter can generally lie between 3 and 6 mm.

The total length of the probe without connection means is typically approximately 35 cm, the handle being approximately 20 cm long, the shaft approximately 10 cm,



and the end approximately 2 cm. In general, the length of the shaft 5 lies between 8 and 15 cm, and the shaft has a diameter between 3 and 6 mm and is made of a physiologically acceptable plastic. Suitable plastics are nylon 66, 5 polypropylene and high-density polyethylene.

C L A I M S

1. Instrument for making at least one stripe-shaped transmural lesion in an operation in one or more walls of the atria of the heart, which lesion essentially blocks the electrical impulse conduction in a direction crosswise to the stripe-shaped transmural lesion, characterized in that the instrument is a probe in which the end (2) which comes into contact with the wall to be treated during the operation is a closed electrode which can interact with an RF power source, while the probe is of a relatively rigid type.
2. Instrument according to claim 1, characterized in that the probe has at least a handle (1); an end (2); a relatively rigid shaft (5) between the handle (1) and the end (2), and connecting and conduction means (6, 7) for connecting the end (2) of the probe to the RF power source.
3. Instrument according to claim 1 - 2, characterized in that in the end (2) of the probe a temperature recorder (3) is present, which temperature recorder, operating in a feedback system with the RF power source, can regulate the temperature of the end (2) of the probe to a preset value.
4. Instrument according to one or more of the preceding claims, characterized in that said instrument can interact with means for supplying a physiologically acceptable liquid to the end (2) of the probe.
5. Instrument according to claim 4, characterized in that the means for supplying a physiologically acceptable liquid to the end (2) of the probe form part of the probe.
6. Instrument according to claim 4 - 5, characterized in that between the handle (1) of the probe and the shaft (5) inlet means (12) are accommodated, for introducing the physiologically acceptable liquid, and inside the shaft (5) electrically insulated throughflow of said liquid to the end of the probe can occur, while near the end (2) discharge means (14) for the liquid are present.
7. Instrument according to one or more of the preceding claims 2 - 6, characterized in that at the side

- of the handle (1) facing away from the end (2) of the probe the conduction and connecting means (6, 7) of the probe comprise a connector (8, 9) connected thereto and having contact means for connection of the end (2) and the temperature recorder (3) to the RF power source.
- 5 8. Instrument according to claim 2, characterized in that the shaft (5) has an intrinsic curvature (4).
9. Instrument according to claim 8, characterized in that the curvature (4) is approximately 140 degrees.
- 10 10. Instrument according to one or more of the preceding claims 2 - 9, characterized in that the length of the shaft (5) lies between 8 and 15 cm, and the shaft has a diameter between 3 and 6 mm and is made of a physiologically acceptable plastic.




Fig. 1




Fig. 2




Fig. 3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/NL 97/00223

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61B18/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 013 312 A (PARINS) 7 May 1991 see column 3, line 11 see column 3, line 12 - line 15 see column 3, line 42 - line 52 see column 4, line 20 - line 30; figure 1 ---	1,2
X	WO 95 19148 A (ENDO VASCULAR, INC.) 20 July 1995 see page 3, paragraph 5 see page 3, paragraph 2 see page 4, line 3 see page 6, paragraph 6 see page 7, paragraph 3 see page 8, paragraph 6; figures 1,2 ---	1,3
Y	---	4
Y	WO 95 17222 A (ANGEION CORP.) 29 June 1995 see abstract; figure 16 ---	4
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

14 August 1997

Date of mailing of the international search report

28.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Papone, F

# INTERNATIONAL SEARCH REPORT

Internat. J. Application No.

PCT/NL 97/00223

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 280 972 A (SIEMENS) 7 September 1988 (cited in search report of original NL application ) ---	
A	US 4 920 978 A (COLVIN) 1 May 1990 (cited in search report of original NL application) ---	
A	EP 0 543 123 A (DELMA) 26 May 1993 (cited in s.r. of original NL application) -----	



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.  
PCT/NL 97/00223

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5013312 A	07-05-91	CA 2036579 A EP 0453071 A JP 4221539 A	20-09-91 23-10-91 12-08-92
WO 9519148 A	20-07-95	US 5437664 A CA 2181453 A EP 0740533 A US 5556396 A US 5643257 A	01-08-95 20-07-95 06-11-96 17-09-96 01-07-97
WO 9517222 A	29-06-95	US 5462521 A AU 1866695 A CA 2179711 A EP 0746372 A US 5643197 A	31-10-95 10-07-95 29-06-95 11-12-96 01-07-97
EP 280972 A	07-09-88	NONE	
US 4920978 A	01-05-90	NONE	
EP 543123 A	26-05-93	DE 4138115 A DE 59205754 D US 5277696 A	27-05-93 25-04-96 11-01-94

**THIS PAGE BLANK (USPTO)**